Claims for Patent: 7,112,324

Summary for Patent: 7,112,324

Title:	CD 19.times.CD3 specific polypeptides and uses thereof
Abstract:	Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
Inventor(s):	Dorken; Bernd (Berlin, DE), Riethmuller; Gert (Munich, DE), Kufer; Peter (Moosburg, DE), Lutterbuse; Ralf (Munich, DE), Bargou; Ralf (Berlin, DE), Loffler; Anja (Finowfurt/Eichhorst, DE)
Assignee:	Micromet AG (Munich, DE)
Application Number:	09/673,735
Patent Claims:	1. A single-chain multi-functional polypeptide comprising (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD19 antigen; and (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V.sub.LCD19-V.sub.HCD19-V.sub.HCD3-V.sub.LCD3. 2. The polypeptide of claim 1, wherein said two domains are connected by a polypeptide linker. 3. The polypeptide of claim 1, wherein said first and/or second domain correspond to a V.sub.H and V.sub.L region from a natural antibody. 4. The polypeptide of claim 1, wherein said antibody is monoclonal antibody, synthetic antibody, or humanized antibody. 5. The polypeptide of claim 4, wherein at least one of said domains is a single-chain fragment of the variable region of the antibody. 6. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of glycine, alanine, serine residues or combinations thereof. 7. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of consecutive copies of an amino acid sequence. 8. The polypeptide of claim 2, wherein said polypeptide linker comprises 1 to 5 amino acid residues. 9. The polypeptide of claim 8, wherein said polypeptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser. 10. The polypeptide of claim 1, wherein (a) said binding site of the first domain has an affinity of at least about 10.sup.-7 M; and/or (b) said binding site of the second domain has an affinity of less than about 10.sup.-7 M. 11. The polypeptide of claim 1, wherein said polypeptide is a bispecific single-chain antibody. 12. The polypeptide of claim 1, comprising at least one further domain. 13. A The polypeptide of claim 12, wherein said further domain is linked by covalent or non-covalent bonds. 14. The polypeptide of claim 12, wherein said at least one further domain comprises an effector molecule having a conformation suitable for biological activity, capable of sequestering an ion or selective binding to a solid support or to a preselected determinant. 15. A method for the preparation of a single-chain multi-functional polypeptide comprising: cultivating a cell transfected with a polynucleotide which upon expression encodes the single-chain multi-functional polypeptide of claim 1; and isolating said polypeptide from the cell. 16. A composition comprising a single-chain multi-functional polypeptide comprising: (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD 19 antigen; and (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V.sub.LCD19-V.sub.HCD19-V.sub.HCD3-V.sub.LCD3. 17. The composition of claim 16 which is a pharmaceutical composition optionally further comprising a pharmaceutically acceptable carrier. 18. The composition of claim 16, which is a diagnostic composition optionally further comprising suitable means for detections. 19. A method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells comprising administering to a human afflicted with said malignancies, diseases or depletion, an effective amount of a single-chain multi-functional polypeptide comprising: (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD 19 antigen; and (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V.sub.LCD19-V.sub.HCD19-V.sub.HCD3-V.sub.LCD3. 20. The method of claim 19, wherein said B-cell malignancy is non-Hodgkin lymphoma. 21. The method of claim 15, wherein said first and/or second domain correspond to a V.sub.H and V.sub.L region from a natural antibody. 22. The method of claim 19, wherein the single-chain multi-functional polypeptide comprises at least one further domain. 23. The method of claim 19, wherein said first and/or second domain correspond to a V.sub.H and V.sub.L region from a natural antibody.

Details for Patent 7,112,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	BLINCYTO	blinatumomab	For Injection	125557	12/03/2014		2018-04-21

International Patent Family for US Patent 7,112,324

Country	Patent Number	Estimated Expiration
Austria	244758
Australia	4135299
Australia	761587
Brazil	9909860